61. (New) A compound having a Formula I:



wherein

A^2 is a single or fused ring, each ring constituting A^2 is an aliphatic or aromatic ring which may have at least one hetero atom, each ring constituting A^2 may be substituted by at least one group selected from halogen, hydroxy, alkyl, cycloalkyl, alkoxy, perfluoroalkyl, perfluoroalkoxy, cyano, nitro, mercapto, acyl, amino, acylamino and aryl,

M^1 is alkylene which may be substituted by halogen, hydroxy, $(C_1\text{-}C_5)$alkyl, and / or $(C_1\text{-}C_5)$alkoxy,

B is alkyl, cycloalkyl, aryl, arylalkyl, hydroxyarylalkyl, aryloxyarylalkyl or arylalkoxyalkyl,

R is hydrogen, alkyl, or cycloalkyl,

D is



or



wherein

R^1 is hydrogen, alkyl, or cycloalkyl, and

R^2 and R^3 are independently hydrogen, alkyl, hydroxyl alkyl, arylalkyl which may be substituted on its aromatic ring, or arylalkoxyalkyl which may be substituted on its aromatic ring, acyl, amidino, alkoxycarbonyl, or either R^2 or R^3 can be taken together with R^1 to form alkylene, and

R^2 and R^3 can be taken together with the nitrogen atom to which R^2 and R^3 are bonded to form a heterocycle, and

M^2 is :





or



wherein

x, y and z are independently an integer of 0 to 4, and

R^5, R^6, R^7 and R^8 are independently hydrogen, halogen, alkyl, $-OR^9$, $-SR^9$, $-NR^9R^{10}$, $-NHC(O)R^9$, $-C(O)OR^9$, $-OCOR^9$, $-OC(O)OR^9$, $-CONR^9R^{10}$, or can be taken together with R^1 or R^2 and the bridging group which links R^5, R^6, R^7 or R^8 to R^1 or R^2 to form a carbocycle or heterocycle,

R^9 and R^{10} are independently hydrogen or alkyl, and

R^9 can be taken together with R^1 or R^2 to form alkylene,

R^5 and R^7, or R^6 and R^8 can be taken together with the carbon atoms to which R^5 and

R^7, or R^6 and R^8 are bonded to form a carbocycle or heterocycle, or

R^5 and R^6, or R^7 and R^8 can be taken together with the carbon atom to which R^5 and R^6, or R^7 and R^8 are bonded, respectively, to form carbonyl, thiocarbonyl or imino, and

E is oxygen atom or sulfur atom,

and pharmaceutically acceptable salts and individual isomers thereof.

62. (New) A compound, and pharmaceutically acceptable salts and individual isomers thereof according to Claim 61 wherein A^2 is :



wherein

A^3 is a 5, 6, or 7 membered aromatic ring which may include at least one hetero atom, and may be substituted by a group selected from halogen, hydroxy, (C_1-C_5)alkyl, (C_1-C_5)alkoxy, (C_1-C_5)perfluoroalkyl, (C_1-C_5)perfluoroalkoxy, nitro, cyano, mercapto, amino, acylamino, acyl and / or phenyl, or

A^3 can be fused with at least 5 to 8 membered aliphatic or aromatic ring which may include at least one hetero atom, and

l is 0, 1, or 2, and

X is $-CH_2-$, -O-, -S(O)r-, -C(O)-, -C(S)-, -CH=CH-, -CH(OH)-, or $-NR^4-$, and

R^4 is hydrogen, (C_1□C_5)alkyl, (□C_8)cycloalkyl, acyl, or alkoxycarbonyl, and

m is 0, 1, or 2, and

Y is -C(O)-, -C(S)-, or (C_1-C_5)alkylene which may be substituted by (C_1-C_5)alkyl,

p is 0, 1, or 2, and

r is 0,1, or 2, and

Z is substituted or unsubstituted(C_1-C_5)alkylene,$-NR^4-$, or



wherein

A^4 is a 5 or 6 membered aromatic ring which may be comprised of at least one hetero atom, and

A^4 may be substituted by a group selected from halogen, hydroxy, (C_1-C_5) alkyl, (C_1-C_5)alkoxy, (C_1-C_5)perfluoroalkyl, (C_1-C_5)perfluoroalkoxy, nitro, cyano, amino, acylamino and/or phenyl, or



wherein

G_1 and G_2 are independently carbon or nitrogen, and

one of ---- may represent double bond when either G_1 and G_2 or G_2 and G_3 are carbon, and

G_3, G_4, and G_5 are independently -O-, -S(O)r-, -C(O)-, -C(S)-, -CH=CH-, -CH(OH)-, -NR^{4-}, or (C_1-C_5)alkylene ,

r is 0, 1, or 2, and

n is 0 or 1.

63. (New) A compound, and pharmaceutically acceptable salts and individual isomers thereof according to Claim 61 wherein A^2 is selected from :

10,11-Dihydrodibenzo[b,f][1,4]oxazepin-11-one,

3,4-Dihydro-2H-quinoline,

2-Oxo-3,4,5,6-tetrahydro-2H-benzo[b]azocine,

2,3-Dioxo-2,3-dihydro-indole,

2-Oxo-3,4-dihydro-2H-quinoline,

3-Oxo-2,3-dihydro-pyrido[3,2-b][1,4]oxazine,

4-Methyl-2,5-dioxo-2,3,4,5-tetrahydro-benzo[e][1,4]diazepine,

2,3-Dihydro-1H-pyrrolo[2,1-c] [1,4]benzodiazepin-5,11(10H,11aH)-dione,

3-Oxo-2,3-dihydro-benzo[l,4]thiazine,

6-Oxo-11,12-dihydro-6H-dibenzo[b,f]azocine,

2-Oxo-2,3,4,5-tetrahydrobenzo[b]azepine,

1,1,4-Trioxo-2,3- dihydro-benzo[1,5]thiazepine,

4-Oxo-2,3-dihydro-1,5-benzothiazepine,

5,11-Dihydro-dibenzo[b,e]azepine,

5H-Dibenzo[b,e]azepin-6,11-dione,

5H-Dibenzo[b,f]azocin-6-one,

10H-Dibenzo[b,f][1,4]thiazepin-11-one,

5-Oxo-5,10H-dibenzo[b,f][1,4]thiazepin-11-one,

5,5-Dioxo-5,10H-dibenzo-[b,f][1,4]thiazepin-11-one,

4-Oxo-2,3-dihydro-[1,5]benzoxazepine,

6,12-Dioxo-6,6a,7,8,9,10-exahydro-12H-benzo[e]-pyrido[1,2-a][1,4]diazepine,

2-Oxo-2H-cyclohepta-4,6,8-trieno[b]pyrrole and

phenothiazine, each of which may be substituted.

64. (New) A compound, and pharmaceutically acceptable salts and individual isomers thereof according to Claim 61 wherein :

B is phenylalkyl, naphthylalkyl, 5,6,7,8-tetrahydro-naphthylalkyl, indolylalkyl, quinolylalkyl, or phenylalkoxyalkyl, which may be substituted by a group selected from halogen, hydroxy, (C_1-C_5)alkyl, (C_1-C_5)alkoxy, nitro, cyano, amino, amino, phenyl, or phenyl.

65. (New) A compound, and pharmaceutically acceptable salts and individual isomers thereof according to Claim 61 wherein:

R^1 is hydrogen, $(C_1$-$C_5)$alkyl, $(C_3$-$C_8)$cycloalkyl, $(C_1$-$C_5)$hydroxyalkyl, or $(C_1$-$C_5)$aminoalkyl, and

R^2 and R^3 are independently hydrogen, $(C_1$-$C_5)$alkyl, $(C_1$-$C_5)$alkyl, $(C_1$-$C_6)$acyl, or $(C_1$-$C_6)$alkoxycarbonyl, and

R^1 and R^2 or R^2 and R^3 are can be taken together to form alkylene,

R^5, R^6, R^7, and R^8 are independently hydrogen, halogen, $(C_1$-$C_5)$alkyl, $(C_1$-$C_5)$alkyl, $-OR^9$, $-SR^9$, $-NR^9R^{10}$, $-OC(O)OR^9$, $-NHC(O)R^9$, $-C(O)OR^9$, and R^5 can be taken together with R^1 or R^2 to form alkylene,

R^9 and R^{10} are independently hydrogen, $(C_1$-$C_5)$alkyl, and

R^9 can be taken together with R^1 or R^2 to form alkylene.

66. (New) A compound, and pharmaceutically acceptable salts and individual isomers thereof according to claim 65 wherein D is selected from:







or

67. (New) A compound selected from:

N-(2-Aminoethyl)-3-phenyl-2(R)-[2-(1,1,4-trioxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)-acetylamino]propionamide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(2-oxo-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl)propionamide;

3-(3-Acetylamino-2-oxo-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl)-N-[1(R)-(2-amino-ethylcarbamoyl)-2-(naphthalen-2-yl)ethyl]propionamide;

N-[1(R)-(2-Aminoethylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(6-oxo-11,12-dihydro-6H-dibenzo[b,f]azocin-5-yl)propionamide;

N-[1(R)-(3-Amino-propylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(6-oxo-11,12-dihydro-6H- dibenzo[b,f]azocin-5-yl)propionamide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(4-oxo-2,3-dihydro[1,5] benzothiazepin-5-yl)propionamide;

N-[1(R)-(4-Aminobutylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(4-oxo-2,3-dihydro- [1,5] benzothiazepin-5-yl)propionamide;

N-(4-Aminobutyl)-3-(naphthalen-2-yl)-2(R)-[2-(4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)-acetylamino]propionamide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(11-oxo-11H-dibenzo [b,f][1,4]oxazepin-10-yl)propionamide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(5,11-dioxo-2,3-dihydro-1H-(11aS)-pyrrolo[2,1-c][1,4]benzodiazepin-10-yl)propionamide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(6-methoxy-2-oxo-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl)propionamide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(4-oxo-2,3-dihydro-[1,5] benzothiazepin-5-yl)butyramide;

N-[1(R)-(4-Aminobutylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(4-methyl-2,5-dioxo-2,3,4,5-tetrahydro-benzo[e][1,4]diazepin-1-yl)propionamide;

N-[1(R)-(2-Aminoethylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(3-oxo-2,3-dihydro-benzo[3,2-b][1,4]oxazin-4-yl)propionamide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(3-oxo-2,3-dihydro-benzo[1,4]oxazin-4-yl)propionamide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(2-oxo-3,4,5,6-tetrahydro-2H-benzo[b]azocin-1-yl)propionamide;

Sub E1

N-(2-Amino-2-methylpropyl)-3-(naphthalen-2-yl)-2(R)-[3-(4-oxo-2,3-dihydro-[1,5] benzothiazepin-5-yl)-propionylamino]propionamide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(2-methyl-4-oxo-2,3-dihydro[1,5]benzothiazepin-5-yl)propionamide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(6-oxo-11,12-dihydro-6H-dibenzo[b,f]azocin-5-yl)butyramide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(3-oxo-2,3-dihydro-benzo[1,4]thiazin-4-yl)butyramide;

N-[1(R)-(3-Methylamino-propylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)propionamide;

N-[1(R)-(3-Methylamino-propylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)butyramide;

N-(1(R)-[(3-Aminopropyl)-methylcarbamoyl]-2-(naphthalen-2-yl)ethyl)-4-(4-oxo-2,3-dihydro-[1,5] benzothiazepin-5-yl)butyramide;

N-(3-Amino-2-hydroxypropyl)-3-(naphthalen-2-yl)-2(R)-[3-(4-oxo-2,3-dihydro-[1,5] benzothiazepin-5-yl)-propionylamino]propionamide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(4-oxo-2,3-

dihydro-[1,5]benzothiazepin-5-yl)butyramide;

N-[1(R)-(2-Amino-ethylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)butyramide;

N-(1(R)-[Bis-(3-aminopropyl)carbamoyl]-2-(naphthalen-2-yl)ethyl)-4-(4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)butyramide;

N-[1(R)-(3-Amino-propylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(1,1,4-trioxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)butyramide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(11-oxo-11H-dibenzo[b,f][1,4]oxazepin-10-yl)butyramide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-phenothiazin-10-yl-propionamide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(6-oxo-11,12-dihydro-6H-dibenzo[b,f]azocin-5-yl)propionamide;

N-(3-Amino-2-hydroxypropyl)-2(R)-[3-(6-methoxy-2-oxo-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl)propionylamino]-3-(naphthalen-2-yl)propionamide;

N-(3-Amino-2-hydroxypropyl)-3-(naphthalen-2-yl)2(R)-[3-(2-oxo-2,3,4,5-tetrahydro-benzo [b]azepin-1-yl)propionylamino]propionamide;

N-(3-Amino-2-hydroxypropyl)-3-(naphthalen-2-yl)-2(R)-[3-(2-oxo-3,4,5,6-tetrahydro-2H-benzo [b]azocin-1-yl)propionylamino]propionamide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-5-(4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)pentanamide;

N-[1(R)-(2-aminoethylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-5-(4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)pentanamide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(1H-indol-3-yl)-ethyl]-4-(4-oxo-2,3-dihydro-[1,5]-benzothiazepin-5-yl)butyramide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(5,6,7,8-tetrahydro-naphthalen-2-yl)ethyl]-4-(4-oxo-2,3-dihydro-[1,5]-benzothiazepin-5-yl)butyramide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(11-oxo-11H-dibenzo[b,f][1,4]oxazepin-10-yl)propionamide;

Sub E1

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(1,4-dioxo-2,3-dihydro-[1,5] benzothiazepin-5-yl)butyramide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(4-oxo-2,3-dihydro-[1,5]-benzoxazepin-5-yl)butyramide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamyl)-2-(naphthalen-2-yl)ethyl]-3-(2-methyl-4-oxo -2,3-dihydro[1,5]benzothiazepin-5-yl)propionamide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(7-fluoro-4-oxo-[1,5]benzothiazepin-5-yl)propionamide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(5,11-dioxo-2,3-dihydro-1H,(11aS)-pyrrolo[2,1-c][1,4]diazepin-10-yl)propionamide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(phenothiazin-10-yl)propionamide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(6-methoxy-2-oxo-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl)butyramide;

N-[1(R)-(2-Aminoethylcarbamoyl)-2-(naphthalene-2-yl)ethyl]-3-(8-fluoro-4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)propionamide;

N-(3-Amino-2-hydroxypropyl)-3-(naphthalene-2-yl)-2(R)-[3-(4-oxo-7-trifluoromethyl-

2,3-dihydro-[1,5]benzothiazepin-5-yl)propionylamino]propionamide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(4-oxo-2,3-dihydro-[1,5]-benzoxazepin-5-yl)butyramide;

N-(3-Amino-2-hydroxypropyl)-3-(naphthalen-2-yl)-2(R)-[3-(4-oxo-2,3-dihydro-[1,5]-benzoxazepin-5-yl)propionylamino]propionamide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(8-fluoro-4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)butyramide;

N-(3-Amino-2-hydroxypropyl)-2(R)-[3-(8-fluoro-4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)propionylamino]-3-(naphthalen-2-yl)propionamide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(8-fluoro-4-oxo-[1,5]-benzothiazepin-5-yl)butyramide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(6-oxo-6,11-dihydro-dibenzo[b,e]azepin-5-yl)propionamide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(6-oxo-6,11-dihydro-dibenzo[b,e]-azepin-5-yl)propionamide;

N-[1(R)-(2-Aminoethylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(6,11-dioxo-6,11-dihydro-dibenzo[b,e]azepin-5-yl)propionamide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(6,11-dioxo-6,11-dihydro-dibenzo[b,e]azepin-5-yl)propionamide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(6,11-dioxo-6,11-dihydro-dibenzo-[b,e]-azepin-5-yl)propionamide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-5-(6-oxo-6H-dibenzo[b,f]azocin-5-yl)pentanamide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-5-(6-oxo-6H-dibenzo[b,f]azocin-5-yl)pentanamide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(11-oxo-11H-dibenzo[b,f][1,4]thiazepin-10-yl)propionamide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(11-oxo-11H- dibenzo[b,f][1,4]-thiazepin-10-yl)propionamide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-5-(5,11-dioxo-5,11-dihydrodibenzo-[b,f][1,4]thiazepin-10-yl)pentanamide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-5-(5,5,11-trioxo-5,11-dihydro-dibenzo[b,f][1,4]thiazepin-10-yl)pentanamide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(2,2-dimethyl-4-oxo-3,4-dihydro-2H-benzo[1,5]thiazepin-5-yl)propionamide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(7-chloro-5,11-dioxo-2,3,11,11a-tetrahydro-1H,5H-benzo[e]pyrrolo[1,2-a][1,4]diazepine-10-yl) propionamide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(6,12-dioxo-6,6a,7,8,9,10-hexahydro-12H-benzo[e]pyrido[1,2-a][1,4]diazepine-5-yl)propionamide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(9-fluoro-2-oxo-3,4,5,6-tetrahydro-2H-benzo[b]azocin-1-yl)propionamide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-2-methyl-3-(4-oxo-3,4-dihydro-2H-benzo[1,5]-thiazepin-5-yl)propionamide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-2-methyl-3-(4-oxo-3,4-dihydro-2H-benzo[1,5]thiazepin-5-yl)propionamide;

N-[1(R)-(3-amino-2(S)-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(4-oxo-3,4-dihydro-[1,5]-benzothiazepin-5-yl)butyramide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-2-methyl-3-(5,11-dioxo-2,3,11,11a-tetrahydro-1H,5H-benzo[e]pyrrolo[1,2-a][1,4]diazepine-10-yl) propionamide;

N-[1(R)-(3-amino-2(R)-hydroxy-propylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(4-oxo-3,4-dihydro-[1,5]-benzothiazepin-5-yl) butanamide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-2,2-dimethyl-3-(5,11-dioxo-2,3,11,11a-tetrahydro-1H,5H-benzo[e]pyrrolo[1,2-a][1,4]diazepine-10-yl) propionamide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-2,2-dimethyl-3-(1,1,4-trioxo-benzo-[1,5]thiazepin-5-yl)propionamide;

N-[1(R)-(3-Amino-ethylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-2-methyl-3-(4-oxo-3,4-dihydro-[1,5]benzothiazepin-5-yl)propionamide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(4-oxo-3,4-dihydro[1,5]benzothiazepin-5-yl)butyramide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(3-cyano-5-isopropyl-2-oxo-2H-cyclohepta-4,6,8-trieno[b]pyrrol-1-yl)propionamide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(5,11-dioxo-2,3, 11,11a-tetrahydro-1H,5H-benzo[e]pyrrolo[1,2-a][1,4]diazepin-10-yl)propionamide; and

N-[1(R)-[2-Hydroxy-3-(2(R)-hydroxypropylamino)propylcarbamoyl]-2-naphthalen-2-yl-ethyl]-4-(4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)butyramide.

68 (New) A composition which comprises an inert carrier and a compound according to claim 61.

69. (New) A composition which comprises an inert carrier, a compound according to claim 61 and at least one of the following components:

a growth hormone secretagogues selected from KP-102(GHRP-2),GHRP-6, Hexarelin, GHRP-1, L-692,429, L-692,585, MK-0677 and G-7220,

a growth hormone releasing factor (GRF) selected from IGF-1, IGF-2 and B-HT920, and

a growth hormone.

70. (New) A method for increasing levels of endogenous growth hormones in a human or an animal which comprises administering to such human or animal an effective amount of a compound according to claim 61.

71. (New) A method for treating diseases or conditions which may be treated by growth hormone which comprises administering to a human or an animal of such treatment an amount of a compound according to claim 61 which is effective in promoting release of said growth hormone.

72. (New) A method of claim 71 wherein the disease or condition is selected from the group consisting of osteoporosis; catabolic illness; immune deficiency, hip fracture; musculoskeletal impairment in the elderly; growth hormone deficiency in adults or in children; obesity; cachexia and protein loss due to chronic illness and treatment of patients recovering from major surgery, wounds and burns.

73. (New) A method for increasing the level of growth hormone in a human or an animal which comprises administering to a human or animal a compound according to claim 61 in combination with any one of the following components:

an additional growth hormone secretagogue selected from KP-102(GHRP-2), GHRP-6, Hexarelin and GHRP-1, a growth hormone releasing factor(GRF) selected from IGF-1, IGF-2 and B-HT920, and a growth hormone.

74. (New) A method for the treatment of osteoporosis which comprises administering to a patient with osteoporosis a combination of a bisphosphonate compound and a compound according to claim 61.

75. (New) A method for the treatment of bone fractures, wounds or burns which comprises administering to a patient with bone fractures, wounds or burns a combination of fibroblast growth factor (FGF) or platelet-derived growth factor (PDGF) and a compound of claim 61.

76. (New) A method to increase the rate and extent of growth of animals, to increase the milk or wool production of animals the method comprising administering to a subject in need thereof an effective amount of a compound according to claim 61.

77. (New) A process for the preparation of a compound of claim 61 which comprises reacting a compound having a formula:

$$A - CO - R^{11}$$

wherein R^{11} is a leaving group with a compound having a formula:



78. (New) A compound, and pharmaceutically acceptable salts and individual isomers thereof according to claim 61 wherein D is selected from:



and

79. (New) A compound, and pharmaceutically acceptable salts and individual isomers thereof according to claim 61 wherein R is hydrogen.

80. (New) A compound, and pharmaceutically acceptable salts and individual isomers thereof according to claim 62 wherein A^2 is selected from:



and

81. (New) A compound, and pharmaceutically acceptable salts and individual isomers thereof according to Claim 79 wherein M^1 is selected from:



and

82. (New) A compound, and pharmaceutically acceptable salts and individual isomers thereof according to Claim 79 wherein B is alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, or aryl, arylalkyl or arylalkoxyalkyl which may be substituted on their aromatic ring.

83. (New) A compound, and pharmaceutically acceptable salts and individual isomers thereof according to claim 81 wherein D is selected from:







and

84. (New) A compound, and pharmaceutically acceptable salts and individual isomers thereof according to claim 81 wherein D is selected from:



and